Drugs / PF-06414300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06659250 | Sep 2024 → Aug 2025 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06414300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06659250 ↗ |
| Route | Oral | “Participants will receive oral ascending doses.” NCT06659250 ↗ |